Cell Growth & Differentiation, Vol 5, Issue 2 171-178, Copyright © 1994 by American Association of Cancer Research

ARTICLES

The biological effects of antisense N-myc expression in human neuroblastoma

ML Schmidt, HR Salwen, CF Manohar, N Ikegaki and SL Cohn
Department of Pediatrics, University of Illinois, Chicago 60612.

Although N-myc amplification and overexpression are believed to play an important role in determining the clinical behavior of neuroblastoma (NB), the exact function of N-myc in NB cell growth and differentiation remains unknown. To better understand the function of N-myc, an established human NB cell line was transfected with N-myc antisense (AS) complementary DNA in an effort to down-regulate N-myc gene expression. Five clones expressing AS N-myc RNA have been maintained in culture for over 2 years. Compared to control cells, a 30-69% decrease in the quantity of N-myc protein was demonstrated by Western blot analysis in 4 of the 5 AS clones. All 5 of the AS clones exhibited a 50-75% decrease in colony formation in soft agar assays compared to control cells. In addition, all 5 AS clones expressed a 3.2-kilobase protein kinase C-alpha transcript, whereas this message was not detected by Northern blot analysis in any of the control clones. These results suggest that N-myc may play an important role in NB cell growth and that antisense N-myc expression is associated with an induction of protein kinase C-alpha RNA expression. Further characterization of the AS clones may provide insight into the function of N-myc and may thus lead to a better understanding of the role that N-myc plays in determining the clinical behavior of this childhood neoplasm.

This article has been cited by other articles:

				E. A. Beierle, A. Trujillo, A. Nagaram, E. V. Kurenova, R. Finch, X. Ma, J. Vella, W. G. Cance, and V. M. Golubovskaya N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma J. Biol. Chem., April 27, 2007; 282(17): 12503 - 12516. [Abstract] [Full Text] [PDF]

				S. Fulda, C. Poremba, B. Berwanger, S. Hacker, M. Eilers, H. Christiansen, B. Hero, and K.-M. Debatin Loss of Caspase-8 Expression Does Not Correlate with MYCN Amplification, Aggressive Disease, or Prognosis in Neuroblastoma. Cancer Res., October 15, 2006; 66(20): 10016 - 10023. [Abstract] [Full Text] [PDF]

				N. Watanabe, H. Sawai, I. Ogihara-Umeda, S. Tanada, E. E. Kim, Y. Yonekura, and Y. Sasaki Molecular Therapy of Human Neuroblastoma Cells Using Auger Electrons of 111In-Labeled N-myc Antisense Oligonucleotides J. Nucl. Med., October 1, 2006; 47(10): 1670 - 1677. [Abstract] [Full Text] [PDF]

				L. Chesler, C. Schlieve, D. D. Goldenberg, A. Kenney, G. Kim, A. McMillan, K. K. Matthay, D. Rowitch, and W. A. Weiss Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma Cancer Res., August 15, 2006; 66(16): 8139 - 8146. [Abstract] [Full Text] [PDF]

				G. Giannini, F. Cerignoli, M. Mellone, I. Massimi, C. Ambrosi, C. Rinaldi, C. Dominici, L. Frati, I. Screpanti, and A. Gulino High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma Cancer Res., September 15, 2005; 65(18): 8308 - 8316. [Abstract] [Full Text] [PDF]

				L. M. Hansford, W. D. Thomas, J. M. Keating, C. A. Burkhart, A. E. Peaston, M. D. Norris, M. Haber, P. J. Armati, W. A. Weiss, and G. M. Marshall Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification PNAS, August 24, 2004; 101(34): 12664 - 12669. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				J. Jaboin, J. Wild, H. Hamidi, C. Khanna, C. J. Kim, R. Robey, S. E. Bates, and C. J. Thiele MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors Cancer Res., November 1, 2002; 62(21): 6108 - 6115. [Abstract] [Full Text] [PDF]

				P. M. Thompson, J. M. Maris, M. D. Hogarty, R. C. Seeger, C. P. Reynolds, G. M. Brodeur, and P. S. White Homozygous Deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma Cancer Res., January 1, 2001; 61(2): 679 - 686. [Abstract] [Full Text]

				K. K. Matthay MYCN Expression in Neuroblastoma: A Mixed Message? J. Clin. Oncol., November 1, 2000; 18(21): 3591 - 3594. [Full Text] [PDF]

				S. L. Cohn, W. B. London, D. Huang, H. M. Katzenstein, H. R. Salwen, T. Reinhart, J. Madafiglio, G. M. Marshall, M. D. Norris, and M. Haber MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN J. Clin. Oncol., November 1, 2000; 18(21): 3604 - 3613. [Abstract] [Full Text] [PDF]

				A. Eggert, N. Ikegaki, J. Kwiatkowski, H. Zhao, G. M. Brodeur, and B. P. Himelstein High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas Clin. Cancer Res., May 1, 2000; 6(5): 1900 - 1908. [Abstract] [Full Text]

				J. M. Maris and K. K. Matthay Molecular Biology of Neuroblastoma J. Clin. Oncol., July 1, 1999; 17(7): 2264 - 2264. [Abstract] [Full Text] [PDF]

				X. X. Tang, A. E. Evans, H. Zhao, A. Cnaan, W. London, S. L. Cohn, G. M. Brodeur, and N. Ikegaki High-Level Expression of EPHB6, EFNB2, and EFNB3 Is Associated with Low Tumor Stage and High TrkA Expression in Human Neuroblastomas Clin. Cancer Res., June 1, 1999; 5(6): 1491 - 1496. [Abstract] [Full Text] [PDF]

				D. Chagnovich and S. L. Cohn Binding of a 40-kDa Protein to the N-myc 3'-Untranslated Region Correlates with Enhanced N-myc Expression in Human Neuroblastoma J. Biol. Chem., December 27, 1996; 271(52): 33580 - 33586. [Abstract] [Full Text] [PDF]

				C. F. Manohar, M. L. Short, A. Nguyen, N. N. Nguyen, D. Chagnovich, Q. Yang, and S. L. Cohn HuD, a Neuronal-specific RNA-binding Protein, Increases the in Vivo Stability of MYCN RNA J. Biol. Chem., January 11, 2002; 277(3): 1967 - 1973. [Abstract] [Full Text] [PDF]